{
    "clinical_study": {
        "@rank": "48635", 
        "arm_group": {
            "arm_group_label": "inhaled nitric oxide", 
            "arm_group_type": "Experimental", 
            "description": "Adults: IK-3001 at start dose 20 ppm; may be increased to 40 ppm at the investigator's or subinvestigator's discretion (up to ~ 24 hrs).\nChildren: IK 3001 at start 10 dose ppm; may be increased to 20 ppm at the investigator's or subinvestigator's discretion (up to ~24 hrs).\nTreatment with IK-3001 will continue until it is clinically indicated to begin the weaning process from IK-3001."
        }, 
        "brief_summary": {
            "textblock": "Sixteen Japanese subjects (6 adults/10 children) with peri- and post-operative pulmonary\n      hypertension associated with cardiac surgery will be evaluated at approx. 6 sites for safety\n      and efficacy of IK-3001."
        }, 
        "brief_title": "Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypertension, Pulmonary", 
            "Ventricular Dysfunction, Left"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary", 
                "Ventricular Dysfunction, Left", 
                "Ventricular Dysfunction"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center, open-label, clinical study of the safety and efficacy of IK-3001 in\n      16 subjects with peri- and post-operative pulmonary hypertension  associated with cardiac\n      surgery. Two primary sub-sets of this patient population will be evaluated in this study:\n\n        1. Adults with severe congestive heart failure having LVAD implant\n\n        2. Children requiring surgery for congenital heart disease with corresponding PH or having\n           Glenn surgery or Fontan surgery for single-ventricle physiology. Children with severe\n           pulmonary hypertension due to congenital heart disease who require inhaled nitric oxide\n           (iNO) pre-operatively may also be enrolled."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects must meet one of the following criteria:\n\n               1. Adults, aged 15 to 80 years, with severe congestive heart failure (CHF) and\n                  scheduled for left ventricular assist device (LVAD) placement; or\n\n               2. Children, aged < 15 years, scheduled for surgery for congenital heart disease\n                  which may associate pulmonary hypertension (PH)(including children with severe\n                  PH due to congenital heart failure and with severe hypoxemia secondary to high\n                  pulmonary vascular resistance or either a history or a possibility of developing\n                  PH crisis, who are deemed by an investigator or subinvestigator to require\n                  IK-3001 pre-operatively); or\n\n               3. Children, aged < 15 years, with congenital heart disease and scheduled for Glenn\n                  surgery; or\n\n               4. Children, aged < 15 years, with congenital heart disease and scheduled for\n                  Fontan surgery.\n\n          2. For women of childbearing potential, a negative result for a pregnancy test\n             documented prior to enrollment.\n\n          3. Subjects must give written informed consent. If the subject is a minor the subject's\n             legally acceptable representative (parent or legal guardian) must give written\n             informed consent.\n\n        Exclusion Criteria:\n\n          1. Lung hypoplasia or other pre-existing severe lung disease;\n\n          2. Planned bi-ventricular support;\n\n          3. Participation in another clinical trial of an investigational agent within 28 days\n             from the day of informed consent for this study including subjects who are deemed to\n             carry a residual effect of an investigational product lasting more than 28 days from\n             a previous investigational study;\n\n          4. Subjects with PH secondary to organic obstructive lesions in pulmonary arteries;\n\n          5. Subjects not under mechanical ventilation;\n\n          6. Investigator or subinvestigator decision that the subject is unsuitable for this\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959828", 
            "org_study_id": "IK-3001-CVS-301"
        }, 
        "intervention": {
            "arm_group_label": "inhaled nitric oxide", 
            "intervention_name": "IK-3001", 
            "intervention_type": "Drug", 
            "other_name": "inhaled nitric oxide"
        }, 
        "intervention_browse": {
            "mesh_term": "Nitric Oxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pulmonary hypertension", 
            "cardiac surgery", 
            "Glenn surgery", 
            "fontan surgery", 
            "left ventricular assist device", 
            "LVAD"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "565-8565"
                    }, 
                    "name": "National Cerebral and Cardiovascular Center (Pediatric CV Surgery)"
                }, 
                "investigator": {
                    "last_name": "Hajime Ichikawa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "565-0871"
                    }, 
                    "name": "Osaka University Hospital"
                }, 
                "investigator": {
                    "last_name": "Yoshiki Sawa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "565-8565"
                    }, 
                    "name": "National Cerebral and Cardiovascular Center (Transplantation)"
                }, 
                "investigator": {
                    "last_name": "Takeshi Nakatani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "113-8655"
                    }, 
                    "name": "The University of Tokyo Hospital"
                }, 
                "investigator": {
                    "last_name": "Minoru Ono, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "162-8666"
                    }, 
                    "name": "Tokyo Women's Medical University Hospital"
                }, 
                "investigator": {
                    "last_name": "Kenji Yamazaki, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "183-8561"
                    }, 
                    "name": "Tokyo Metropolitan Children's Medical Center"
                }, 
                "investigator": {
                    "last_name": "Masaru Miura, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "157-8535"
                    }, 
                    "name": "National Center for Child Health and Development"
                }, 
                "investigator": {
                    "last_name": "Yukihiro Kaneko, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Examination of Safety and Effectiveness of IK-3001 (Nitric Oxide for Inhalation) in Japanese Subjects With Pulmonary Hypertension Associated With Cardiac Surgery - Multi-Center, Open-Label, Clinical Study", 
        "overall_contact": {
            "email": "sofia.caamano@ikaria.com", 
            "last_name": "Sofia Caamano", 
            "phone": "908-238-6659"
        }, 
        "overall_official": {
            "affiliation": "INO Therapeutics", 
            "last_name": "Khurram Jamil, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in mean pulmonary artery pressure (mPAP) in Adult subjects (with LVAD)", 
                "safety_issue": "No", 
                "time_frame": "Predose baseline to 24 hours (or final observation, if < 24 hours) (measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy"
            }, 
            {
                "measure": "Change in partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio in Adult subjects (with LVAD)", 
                "safety_issue": "No", 
                "time_frame": "Predose baseline to 24 hours (or final observation, if < 24 hours) (measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy"
            }, 
            {
                "measure": "Change in central venous pressure (CVP) in Children (with congenital heart disease)", 
                "safety_issue": "No", 
                "time_frame": "Predose baseline to 24 hours (or final observation, if < 24 hours)(measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy"
            }, 
            {
                "measure": "Change in partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio in Children (with congenital heart disease)", 
                "safety_issue": "No", 
                "time_frame": "Predose baseline to 24 hours (or final observation, if < 24 hours) (measured at 1 hour, 4 hours, and 24 hours after initiation of IK-3001 therapy"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959828"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "INO Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "INO Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}